Management of Medication-related Osteonecrosis of the Jaw, An Issue of Oral and Maxillofacial Clinics of North America, 1st Edition
Author :
By Salvatore L. Ruggiero, DMD, MD, FACS
Editor Salvatore Ruggiero, DMD, MD and authors review the Diagnosis, Management and Prevention of Medication-related Osteonecrosis of the Jaw. Articles will include: Osteoporosis and bone modulation therapies: indications and outcomes; Antiresorptive
...view more
Editor Salvatore Ruggiero, DMD, MD and authors review the Diagnosis, Management and Prevention of Medication-related Osteonecrosis of the Jaw. Articles will include: Osteoporosis and bone modulation therapies: indications and outcomes; Antiresorptive therapies for the treatment of malignant osteolytic bone disease; Clinical presentation and staging of antiresorptive agent-induced osteonecrosis of the jaw; Epidemiology and risk factors of antiresorptive agent-induced osteonecrosis of the jaw; Basic science research of antiresorptive agent-induced osteonecrosis of the jaw: an update; Pathophysiology of antiresorptive agent-induced osteonecrosis of the jaw: what we know and what we don’t know; The genetics of osteonecrosis of the jaw; Preventive strategies for patients at risk of antiresorptive agent-induced osteonecrosis of the jaw; Non-operative and operative therapies for treatment of antiresorptive agent-induced osteonecrosis of the jaw; The role of anti-angiogenic therapy in the development of osteonecrosis of the jaw; Antiresorptive therapies: what they are and how do they work, and more!
Editor Salvatore Ruggiero, DMD, MD and authors review the Diagnosis, Management and Prevention of Medication-related Osteonecrosis of the Jaw. Articles will include: Osteoporosis and bone modulation therapies: indications and outcomes; Antiresorptive therapies for the treatment of malignant osteolytic bone disease; Clinical presentation and staging of antiresorptive agent-induced osteonecrosis of the jaw; Epidemiology and risk factors of antiresorptive agent-induced osteonecrosis of the jaw; Basic science research of antiresorptive agent-induced osteonecrosis of the jaw: an update; Pathophysiology of antiresorptive agent-induced osteonecrosis of the jaw: what we know and what we don’t know; The genetics of osteonecrosis of the jaw; Preventive strategies for patients at risk of antiresorptive agent-induced osteonecrosis of the jaw; Non-operative and operative therapies for treatment of antiresorptive agent-induced osteonecrosis of the jaw; The role of anti-angiogenic therapy in the development of osteonecrosis of the jaw; Antiresorptive therapies: what they are and how do they work, and more!
Author Information
By Salvatore L. Ruggiero, DMD, MD, FACS, New York Center of Oral and Maxillofacial Surgery
https://www.asia.elsevierhealth.com/management-of-medication-related-osteonecrosis-of-the-jaw-an-issue-of-oral-and-maxillofacial-clinics-of-north-america-9780323413466.html294626Management of Medication-related Osteonecrosis of the Jaw, An Issue of Oral and Maxillofacial Clinics of North Americahttps://www.asia.elsevierhealth.com/media/catalog/product/9/7/9780323413466_7.jpg74.2498.99USDInStock/Clinics/Dentistry/Dentistry (General)/Clinics/Clinics/Dentistry/Dentistry (General)/Japan Titles438872550545675054666525504152598485263160141826924886536505456651451205259847Editor Salvatore Ruggiero, DMD, MD and authors review the Diagnosis, Management and Prevention of Medication-related Osteonecrosis of the Jaw. Articles will include: Osteoporosis and bone modulation therapies: indications and outcomes; Antiresorptive therapies for the treatment of malignant osteolytic bone disease; Clinical presentation and staging of antiresorptive agent-induced osteonecrosis of the jaw; Epidemiology and risk factors of antiresorptive agent-induced osteonecrosis of the jaw; Basic science research of antiresorptive agent-induced osteonecrosis of the jaw: an update; Pathophysiology of antiresorptive agent-induced osteonecrosis of the jaw: what we know and what we don’t know; The genetics of osteonecrosis of the jaw; Preventive strategies for patients at risk of antiresorptive agent-induced osteonecrosis of the jaw; Non-operative and operative therapies for treatment of antiresorptive agent-induced osteonecrosis of the jaw; The role of anti-angiogenic therapy in the development of osteonecrosis of the jaw; Antiresorptive therapies: what they are and how do they work, and more! Editor Salvatore Ruggiero, DMD, MD and authors review the Diagnosis, Management and Prevention of Medication-related Osteonecrosis of the Jaw. Articles will include: Osteoporosis and bone modulation therapies: indications and outcomes; Antiresorptive therapies for the treatment of malignant osteolytic bone disease; Clinical presentation and staging of antiresorptive agent-induced osteonecrosis of the jaw; Epidemiology and risk factors of antiresorptive agent-induced osteonecrosis of the jaw; Basic science research of antiresorptive agent-induced osteonecrosis of the jaw: an update; Pathophysiology of antiresorptive agent-induced osteonecrosis of the jaw: what we know and what we don’t know; The genetics of osteonecrosis of the jaw; Preventive strategies for patients at risk of antiresorptive agent-induced osteonecrosis of the jaw; Non-operative and operative therapies for treatment of antiresorptive agent-induced osteonecrosis of the jaw; The role of anti-angiogenic therapy in the development of osteonecrosis of the jaw; Antiresorptive therapies: what they are and how do they work, and more!00add-to-cart97803234134662015ProfessionalBy Salvatore L. Ruggiero, DMD, MD, FACS20151BookOtherElsevier0Nov 2, 2015IN STOCKBy <STRONG>Salvatore L. Ruggiero</STRONG>, DMD, MD, FACS, New York Center of Oral and Maxillofacial SurgeryClinicsClinicsThe Clinics: SurgeryUnited StatesNoNoNoNoPlease SelectPlease SelectPlease Select